{"related:WWEOAKLK6UcJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5":[{"title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 …","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5455807/","authors":["TK Choueiri","TK Choueiri S Halabi","TK Choueiri S Halabi BL Sanford","TK Choueiri S Halabi BL Sanford O Hahn…"],"year":2017,"numCitations":386,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5455807/","citationUrl":"http://scholar.google.com/scholar?cites=5181895643400921433&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:WWEOAKLK6UcJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5181895643400921433&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"ncbi.nlm.nih.gov","p":1,"exp":1596876833729},{"title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","url":"https://www.sciencedirect.com/science/article/pii/S1470204516301073","authors":["TK Choueiri","TK Choueiri B Escudier","TK Choueiri B Escudier T Powles","TK Choueiri B Escudier T Powles NM Tannir…"],"year":2016,"numCitations":565,"pdf":"https://helda.helsinki.fi/bitstream/handle/10138/224076/Cabozantinib_versus_everolimus.pdf?sequence=1&isAllowed=y","citationUrl":"http://scholar.google.com/scholar?cites=16074541589004785383&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:55bfm2g-FN8J:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16074541589004785383&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Elsevier"},{"title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1510016","authors":["TK Choueiri","TK Choueiri B Escudier","TK Choueiri B Escudier T Powles…"],"year":2015,"numCitations":765,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1510016","citationUrl":"http://scholar.google.com/scholar?cites=15416788208830885159&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:J63LvDFv89UJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15416788208830885159&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Mass Medical Soc"},{"title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","url":"https://www.sciencedirect.com/science/article/pii/S1470204515002909","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson H Glen","RJ Motzer TE Hutson H Glen MD Michaelson…"],"year":2015,"numCitations":540,"pdf":"http://www.academia.edu/download/62011744/The_Lancet_Oncology_Lenvatinib_mRCC_10_15_201520200206-12162-s53hwh.pdf","citationUrl":"http://scholar.google.com/scholar?cites=4253233843226512535&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:l4wvVKWFBjsJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4253233843226512535&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Elsevier"},{"title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) …","url":"https://www.sciencedirect.com/science/article/pii/S0959804918301813","authors":["TK Choueiri","TK Choueiri C Hessel","TK Choueiri C Hessel S Halabi","TK Choueiri C Hessel S Halabi B Sanford…"],"year":2018,"numCitations":121,"pdf":"https://www.sciencedirect.com/science/article/pii/S0959804918301813","citationUrl":"http://scholar.google.com/scholar?cites=14929455411752643417&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:WauM65gUMM8J:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14929455411752643417&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Elsevier"},{"title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1712126","authors":["RJ Motzer","RJ Motzer NM Tannir","RJ Motzer NM Tannir DF McDermott…"],"year":2018,"numCitations":1247,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1712126","citationUrl":"http://scholar.google.com/scholar?cites=13898631485117911629&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:TVKDlrLb4cAJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13898631485117911629&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Mass Medical Soc"},{"title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","url":"https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.578","authors":["RJ Motzer","RJ Motzer T Powles","RJ Motzer T Powles MB Atkins","RJ Motzer T Powles MB Atkins B Escudier…"],"year":2018,"numCitations":165,"citationUrl":"http://scholar.google.com/scholar?cites=1771464359342537550&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:Tnvg_nKBlRgJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","publication":"ascopubs.org"},{"title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","authors":["RJ Motzer","RJ Motzer K Penkov","RJ Motzer K Penkov J Haanen","RJ Motzer K Penkov J Haanen B Rini…"],"year":2019,"numCitations":502,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816047","citationUrl":"http://scholar.google.com/scholar?cites=1882792696390332365&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:za8LXvsFIRoJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1882792696390332365&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Mass Medical Soc"},{"title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","authors":["BI Rini","BI Rini ER Plimack","BI Rini ER Plimack V Stus","BI Rini ER Plimack V Stus R Gafanov…"],"year":2019,"numCitations":545,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1816714","citationUrl":"http://scholar.google.com/scholar?cites=14370914940926626173&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:fQlJl_--b8cJ:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14370914940926626173&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Mass Medical Soc"},{"title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1303989","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson D Cella","RJ Motzer TE Hutson D Cella J Reeves…"],"year":2013,"numCitations":1434,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1303989","citationUrl":"http://scholar.google.com/scholar?cites=5593415504868596567&as_sdt=2005&sciodt=0,5&hl=en&scioq=systemic+therapy","relatedUrl":"http://scholar.google.com/scholar?q=related:V9vaOMTNn00J:scholar.google.com/&scioq=systemic+therapy&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5593415504868596567&hl=en&as_sdt=0,5&scioq=systemic+therapy","publication":"Mass Medical Soc"}]}